Tech Q&A with CARE Research

February 12, 2018 | Posted by Team in Drug Discovery, New Innovations, Research |


 

Chandreyee Das, PhD, of Science Exchange recently spoke with Rajan Bawa, PhD, of CARE Research LLC, a leading preclinical CRO combining quality service for clients with excellent quality of life for animals — even for challenging or complex projects.

CD: Rajan, you’ve been in the pharmaceutical and biotechnology industry for over 40 years, can you tell us your company’s story?

RB: Twenty years ago, I started this histopathology company, Colorado Histo-Prep. In 2010, we acquired one of our preclinical CRO clients, which was CARE Research, enabling us to provide a one-stop-shop for our clients in the preclinical space.

CD: What capabilities does CARE Research have that set the company apart from other preclinical CROs?

RB: One differentiator is our ability to start projects very swiftly, with quick IACUC approval. We have extensive technical and regulatory experience.

Also, our responsiveness to our sponsor needs, being proactive in providing ongoing progress reports — we don’t wait until things go wrong.

We’re relatively small — we have about 20 people — but that means that we have high-ranking people in our organization — say, VP of Toxicology, or IACUC chairs — actively involved in projects. In large preclinical CROs, very often, there’s a study director who sits in his office, doesn’t even make it to the lab until the sponsor comes to visit.

CD: What preclinical services do you offer that are differentiated from other service providers?

RB: One area of strength is in DART (Developmental and reproductive toxicology) studies and ocular studies. DART services are not often offered by small or medium CROs, because they lack the expertise to carry out these specialized studies.

Ocular studies are another of our core competencies — these are also complex studies, you really have to know what you’re doing.

CD: What type of certifications does CARE Research hold?

RB: That’s a great question. We are OLA certified, AAALAC accredited, and we are GLP. We’re inspected regularly by FDA and USDA.

CD: What types of clients do you serve?

RB: We have a mix of different sponsors. We have large pharma, small biomedical companies, university researchers, startup companies.

In addition to our flexibility and ability to respond quickly, we have the ability to do very complex projects, especially in the surgical and ocular area in contrast to other CROs who may stay away from complex studies.

CD: Finally, could you describe your experience with Science Exchange?

RB: Science Exchange allows us to widen our reach, and allows us to find clients we would not have found using our internal resources. Also, the project managers whom I’ve interacted with are very helpful and responsive, and easily available to answer any questions, provide clarifications, etc in a patient manner.

 

Request a quote from CARE Research and get on the fastest path to completing your preclinical studies.

request quotes button

 

Science Exchange Announces Outsourced R&D Collaboration with UC Davis Venture Catalyst Group

February 12, 2018 | Posted by Team in Press Release |

Science Exchange Venture Catalyst Collaboration

Palo Alto, CA – February 12, 2018 — Science Exchange, the world’s leading and most secure enterprise platform for outsourced research and development (R&D), today announced a strategic collaboration with Venture Catalyst, a unit within the Technology Management and Corporate Relations division of the UC Davis Office of Research which supports the development of new ventures fueled by university research.

Science Exchange will provide entrepreneurs and startups participating in the Venture Catalyst Smart Toolkit for Accelerated Research Translation (START™) Program immediate access to the private R&D marketplace with dedicated PhD-level sourcing support around the clock and a special contracting structure to accelerate their research and development projects.

“The Science Exchange platform solves the challenges of R&D outsourcing by providing scientists with on-demand access to a diverse network of prequalified external providers under a single relationship while also providing sourcing departments with more information and control over their outsourcing spending,” said Elizabeth Iorns, Ph.D., co-founder and CEO of Science Exchange. “We are thrilled to be collaborating with Venture Catalyst to offer a customized R&D marketplace and help its portfolio of companies complete their research and clinical projects more quickly and efficiently. It’s clear that Venture Catalyst is supporting companies with extremely promising technologies in development, and we’re honored to help get their discoveries to market faster.”

With this collaboration, Science Exchange will support client-specific governance, approval workflows, and preferred vendors, all the while enabling instant access to research services and custom products from 2,500 providers in over 6,000 research areas. To help external service providers minimize the risk frequently associated with outsourcing,  Science Exchange’s guarantee ensures complete protection of data, assets and performance of agreed-upon services, all backed by the best-in-class, SOC 2-compliant information technology security infrastructure. Science Exchange’s ISO 9001-certified quality assurance system and dedicated regulatory compliance team also support regulated outsourced work.

Venture Catalyst is the latest innovation and startup support organization to choose to partner with Science Exchange. They now join more than 30 enterprise organizations including most of the top 20 biopharma companies that use Science Exchange to more efficiently manage outsourced R&D.

“Science Exchange offers a unique platform for our startups to connect with a broad network of qualified scientific providers,” said Dushyant Pathak, Associate Vice Chancellor of Research and Executive Director of Venture Catalyst at UC Davis. “We anticipate that working with Science Exchange through the START Program will enable us to commercially advance the discoveries made by Venture Catalyst-supported startups and early-stage companies, in areas as diverse as biomedical and life sciences, agriculture and animal health, and physical sciences and engineering.”

 

About Venture Catalyst

Venture Catalyst furthers the University’s educational, research and public mission by supporting UC Davis students, faculty and researchers in translating science, engineering and innovative research through well-resourced startups, into societal impact.  Venture Catalyst engages collaboratively with internal and external drivers of innovation and works closely with the University’s Institute for Innovation & Entrepreneurship.  In addition to its Smart Toolkit for Accelerated Research Translation (START™) program, Science Translation and Innovative Research (STAIR™) Proof-of-Concept grants, Venture Catalyst supports a network of regional technology startup incubators through its Distributed Research Incubation & Venture Engine (DRIVE™) Network.

Rapid Novor Inc. Launches REmAb™ Antibody Protein Sequencing Services on Science Exchange

January 24, 2018 | Posted by Team in Drug Discovery, New Innovations, Press Release, Research |

PALO ALTO, CA, January 25, 2018 – Science Exchange, the world’s leading and most secure enterprise platform for outsourced research and development (R&D) services, announced a partnership with Rapid Novor Inc to offer its REmAb™ Antibody Protein Sequencing Services to scientists around the world using Science Exchange’s R&D platform.

Rapid Novor, Inc. is a Kitchener-Waterloo (Canada)-based CRO dedicated to the development of antibody protein sequencing technologies. The company’s mission is to advance life science research to better human health with next-generation protein sequencing. With the opening of its own state-of-the-art mass spectrometry lab in 2017, the team has successfully sequenced hundreds of monoclonal antibodies directly from the proteins and helped pharmaceutical companies in their antibody drug discovery.

“Our focus is on the development of antibody protein sequencing technologies, and we are the only team that has both a mass spectrometry lab and proprietary sequencing software platform,” said Mingjie Xie, Co-founder and CEO of Rapid Novor, Inc. “We are uniquely positioned to offer superior protein sequencing services to researchers worldwide. The partnership with Science Exchange will allow us to provide easy-to-access services to enterprise biopharma companies and offer them cutting-edge technologies in a seamless manner.”

“We are thrilled to partner with Rapid Novor Inc to make its REmAb™ Antibody Protein Sequencing Services available to scientists worldwide,” said Elizabeth Iorns, Ph.D., co-founder and CEO of Science Exchange. “By partnering with the leading CROs in different research and technology sectors, we are bringing in the best and brightest service providers to our secure and readily available platform so that the scientists can focus on developing breakthrough discoveries. Having Rapid Novor Inc as part of our supplier portfolios is an example of our commitment to making it easy for researchers to access the world’s leading scientific service providers and most innovative scientific technologies.”

About Rapid Novor, Inc.

Rapid Novor, Inc. is the world’s leader in antibody protein sequencing technology. Specializing in the field of mass spectrometry-based proteomics, the team has developed the technology to directly sequence the antibody proteins without needs to access the cell line. As a University of Waterloo spin-off, the company is building its technology portfolios based on the twenty years of scientific research and inventions from Dr. Bin Ma, co-founder and chief scientist. The company’s REmAb™ antibody protein sequencing service has allowed the accurate sequencing of any given antibody proteins routinely. The company’s WILD™ service is the first commercially available service that can accurately distinguish the isomeric isoleucine and leucine using mass spectrometry. For more information, visit www.rapidnovor.com. Follow the company on Twitter @rapidnovor.

Science Exchange Partners with Lab Launch to Help its Startups Advance Scientific Innovations

January 10, 2018 | Posted by Team in Press Release |

Lab Launch Science Exchange Enterprise Outsourcing PlatformPalo Alto, CA – January 10, 2018 — Science Exchange, the world’s leading and most secure enterprise platform for outsourced research and development (R&D), teamed up today with Lab Launch, a nonprofit working to provide affordable and high-quality laboratories to biotech startups. This partnership with Science Exchange allows Lab Launch’s resident companies to easily supplement and complement their in-house resources with external research tools, technologies, and expertise.

Science Exchange enables immediate access to over 2,500+ commercial CROs, academic labs, and government facilities under a single marketplace agreement, in addition to a 24/7 PhD-level support by Science Exchange staff scientists.

“Our goal is to give LA-based scientists and entrepreneurs every opportunity to further their ideas and innovations in a way that is affordable and that will also give them access to the best scientific resources available,” said Marie Rippen, CEO of Lab Launch.  “By partnering with Science Exchange, Lab Launch can now offer our companies access to fully vetted service providers in a secure environment, so our scientists can devote time to advancing their ideas instead of being bogged down with administrative tasks including researching and negotiating with service providers.”

“Lab Launch and Science Exchange are both driven to give scientists the tools and support they need to be successful in developing their breakthrough ideas,” said Elizabeth Iorns, Ph.D., co-founder and CEO of Science Exchange. “Scientists at Lab Launch will now automatically gain access to the best scientific providers to help bring groundbreaking discoveries to market. We are excited to be part of the process!”

Lab Launch is the latest R&D organization to choose to partner with Science Exchange and joins more than 30 enterprise clients and Life Science incubators that are effectively managing their outsourced R&D with Science Exchange-powered marketplaces.

About Lab Launch

Lab Launch Inc is a 501(c)(3) non-profit working to establish a more dynamic biotech startup environment in Los Angeles. Our mission is to enable LA’s scientists and entrepreneurs to develop their ideas in affordable, high-quality lab facilities, with access to services and a supportive innovation community to accelerate their success.

 

Request a demo of Science Exchange’s platform to see how your organization can benefit from increased access to innovation and organizational efficiency.

Innovation Drives Operational Challenges that Impact R&D Productivity

December 21, 2017 | Posted by Team in Drug Discovery, Outsourcing Best Practices |

by Elizabeth Iorns, Ph.D., CEO and Co-Founder, Science Exchange
Originally appeared in the 2017 Fierce Life Science Innovation Report (download PDF)

Fierce LS Innovation Report

R&D productivity and efficiency are key measures for evaluating the success of biotech and pharma companies. In theory, investing resources into R&D to boost those measures should yield positive results. Unfortunately, recent trends suggest a less desirable outcome.

A primary driver of the R&D productivity decline is the prolific growth in innovative therapeutic modalities. The first siRNA therapeutics, CAR-T engineered cells, and viral gene therapies have all been approved by the FDA within the past 2 years alone.  This innovation in the biotech and pharma industry has enabled spectacular successes in the treatment of devastating diseases, but it comes with significant operational challenges.

In contrast to the well-known development process for small molecules, these new highly specialized therapeutics require exponentially more diverse and complex technologies and expertise.  So how do biotech and pharma companies access this evolving set of technology and expertise?  Increasingly, they have shifted to a reliance on an external R&D ecosystem.  By outsourcing, companies can manage fixed costs while accessing specialized technologies, particularly in complex R&D areas. As of 2017, nearly half of R&D budgets are spent on outsourced scientific services and the trend is increasing.

But, several challenges prevent companies from realizing returns on their outsourcing investments.

  • First: even though outsourcing represents a rapid path to new technologies, identifying relevant and qualified service providers is a time-consuming task that can take weeks or even months.
  • Second: contracts required to maintain confidentiality, protect IP, and ensure compliance can delay project initiation and add to transaction costs.
  • Third: R&D organizations may have thousands of individual scientists conducting tens of thousands of outsourced R&D projects each year. Maintaining visibility, monitoring performance, measuring success represent a significant management burden.

Science Exchange directly addresses these challenges and has demonstrated a significant impact on productivity and efficiency in R&D programs around the world.  The Science Exchange platform uniquely provides a marketplace of pre-qualified and pre-contracted outsourced R&D service providers to provide scientists with instant access to the innovative services necessary to advance today’s pipeline.  

Get help leading change at your organization: request a demo of the Science Exchange  platform.

Breakout Labs Partners with Science Exchange to Empower its Portfolio Companies with External Research Innovations

December 18, 2017 | Posted by Team in New Innovations, Press Release, Science Exchange News |

Breakout Labs Science Exchange

Palo Alto, CA – December 18, 2017 — Science Exchange, the world’s leading and most secure enterprise platform for outsourced research and development (R&D), today announced a strategic partnership with Breakout Labs, a fund within the Thiel Foundation that backs scientist-entrepreneurs working at the intersections of technology, biology, materials, and energy. The newly formed partnership allows for Breakout Labs to provide its portfolio companies’ scientists with on-demand access to a global network of research suppliers via the Science Exchange-powered private marketplace.

The private marketplace enables instant access to thousands of research tools, technologies, and services from over 2,500+ commercial CROs, academic labs, and government facilities under a single Science Exchange contract. Additionally, the platform users receive end-to-end PhD-level support from the Science Exchange staff scientists in identifying the best external innovations to expedite their R&D cycles.

“Our companies are small innovative startups that, despite being cash-constrained, are at the forefront of radical scientific breakthroughs,” said Hemai Parthasarathy, Scientific Director of Breakout Labs.  “Science Exchange’s marketplace helps these companies adopt virtualization in their R&D process and give them an opportunity to access external resources they need to bring their innovations to market. Science Exchange fits into the ethos that prompted the formation of Breakout Labs by removing barriers for startups to access scientific services that will help accelerate their discoveries.”

“At Science Exchange, we are passionate about accelerating discovery by making connections — in this case, vital connections between scientist-entrepreneurs and experienced providers of scientific products and services,” said Elizabeth Iorns, Ph.D., co-founder and CEO of Science Exchange. “Through this partnership, the scientists at Breakout Labs’ companies, can now focus on what they do best, bringing game-changing scientific discoveries to market, and rely on us to find the best scientific providers to help them accomplish that.”

Breakout Labs is the latest R&D organization to choose to partner with Science Exchange and join more than 30 enterprise clients and Life Science incubators that are effectively managing their outsourced R&D with Science Exchange-powered marketplaces.

About Breakout Labs

Breakout Labs is a revolving fund within the Thiel Foundation that supports early stage companies as they transition radical scientific advances out of the research lab and into the economy. The program backs bold scientists who work at the intersections of technology, biology, materials, and energy. More than capital, Breakout Labs provides additional support through a two-year program that includes introductions to follow-on funders, corporate partners and other resources to drive commercialization. To learn more, visit: www.breakoutlabs.org.

Science Exchange Wins Two Gold Stevie® Awards in 2017 Stevie Awards for Women in Business

November 21, 2017 | Posted by Team in Company, Press Release, Science Exchange News |

Dr. Elizabeth Iorns Honored as Female Entrepreneur of the Year and Science Exchange as Most Innovative Company of the Year

Gold Stevie Award 2017 Science Exchange

Palo Alto, CA – November 21, 2017 — Science Exchange, the world’s leading and most secure enterprise platform for outsourced research and development (R&D), today announced that CEO and Co-Founder Dr. Elizabeth Iorns, has been named the winner of the Gold Stevie® Award for Female Entrepreneur of the Year. In addition, Science Exchange has been named Most Innovative Company of the Year at the 14th annual Stevie Awards for Women in Business.

The Stevie Awards for Women in Business are the world’s top honors for female entrepreneurs, executives, employees and the organizations they run. The 2017 awards received over 1500 entries from 25 nations and territories; winners were recognized at a November 17 event in New York City.

Dr. Elizabeth Iorns founded Science Exchange in 2011 and has built a global company that has raised over $58M in venture funding. Dr. Iorns has led Science Exchange to rapid growth with enterprise partnerships with the most innovative R&D focused Fortune 100 companies. Science Exchange provides a technology platform for efficient access to the world’s best external R&D partners. Through Science Exchange, scientists can instantly connect and order outsourced scientific projects from over 2,500 top research facilities available under the Science Exchange contract.

“I am honored to receive the Stevie award and be recognized among other inspiring women and companies around the world,” said Dr. Elizabeth Iorns, co-founder and CEO of Science Exchange. “I am also extremely proud of the teams at Science Exchange that work tirelessly with our clients on their outsourced R&D projects to accelerate scientific discovery.”

“The judges were so impressed with the accomplishments of all of the Stevie Award-winning women and organizations. The 2017 Stevie Awards for Women in Business received a record number of nominations and had a record number of ceremony attendees,” said Michael Gallagher, founder and president of the Stevie Awards. “We congratulate all of this year’s Grand, Gold, Silver and Bronze Stevie Award winners for their achievements.”

Details about the Stevie Awards for Women in Business and the list of Stevie Award winners are available at www.StevieAwards.com/Women.  

 

Science Exchange Announces Outsourced R&D Partnership with Alector

November 20, 2017 | Posted by Team in Company, Drug Discovery, Outsourcing Best Practices, Press Release, Science Exchange News |

Science Exchange-Alector PartnershipPALO ALTO, Calif.–Science Exchange, the world’s leading and most secure enterprise platform and aggregator for outsourced research and development (R&D), today announced a strategic partnership with Alector, a biotech company pioneering the discovery & development of immuno-neurology therapies for neurodegenerative disorders, to provide the company’s scientists access to a private R&D marketplace to accelerate their research.

“The Science Exchange platform solves the challenges of R&D outsourcing: we provide scientists with efficient access to a diverse network of qualified suppliers under a single relationship, and at the same time we provide sourcing departments with more information and control over their outsourcing spend,” said Elizabeth Iorns, Ph.D., co-founder and CEO of Science Exchange. “We are thrilled to be the provider of Alector’s R&D marketplace and help bring potential treatments for Alzheimer’s disease to patients more quickly and efficiently. Especially following the exciting news on Alector’s partnership with AbbVie to advance therapies for Alzheimer’s disease, it’s clear that Alector has extremely promising drug targets — we’re honored to help accelerate these important discoveries.”

The Science Exchange-powered R&D marketplace enables scientists to instantly order more than 6,000 unique scientific services from the 2,500 CROs, academic labs, and government facilities that are available under a single Science Exchange contract. The partnership also will provide Alector with a platform to effectively manage the company’s outsourced R&D investments, including the ability to track supplier utilization, trends, and performance, which also supports the need for compliance with internal policies and external regulations.

Alector is the latest R&D company to choose to partner with Science Exchange, and joins more than 30 enterprise organizations, including 10 of the top 20 pharma companies, that use Science Exchange to more efficiently manage outsourced R&D.

“Science Exchange offers a unique platform for connecting with a broad network of qualified scientific service providers,” said Arnon Rosenthal, Ph.D., co-founder and CEO of Alector. “It is our hope that working with Science Exchange will enable us to more quickly advance discovery and development of novel immuno-neurology therapies.”

Under the agreement, Science Exchange will support company-specific governance, approval workflows, and preferred vendors. To minimize the risk frequently associated with outsourcing to external service providers, the Science Exchange guarantee ensures complete protection of data, assets and performance of agreed-upon services, all backed by a best-in-class, SOC 2-compliant information technology security infrastructure. Science Exchange’s ISO 9001-certified quality assurance system and dedicated regulatory compliance team also support regulated work.

 

Visit www.scienceexchange.com/enterprise to request a demo of our award-winning private marketplaces for managing outsourced research and development!

Science Exchange Announces New Director of Scientific Content, Gursatya “Guru” Singh

November 2, 2017 | Posted by Team in Press Release, Science Exchange News |

Guru Singh Science Exchange

PALO ALTO, CA, November 2, 2017Science Exchange, the world’s leading and most secure platform for outsourced research and development (R&D), announced today that Gursatya “Guru” Singh has joined the company’s management team as Director of Scientific Content.

“Adding Guru to our team is part of our ongoing commitment to strengthen the management team with industry experts who are dedicated to disrupting the traditional R&D outsourcing model,” said Elizabeth Iorns, Ph.D., CEO and co-founder of Science Exchange. “Guru’s experience in this industry will help us better inform the scientific community about the benefits of accessing innovation through the Science Exchange platform.”

Singh’s background includes experience as a laboratory researcher and entrepreneur, as he has helped launch several life science startups. This included a previous role where he developed scientific content to promote the innovative services and technologies of scientific service providers. Singh also has published several scientific papers.

A frequent blogger and thought leader in pharma and biotech outsourcing, Singh founded a Facebook group – Mysteries of Biotech – that has amassed nearly 5,000 followers. He holds a master’s degree in biotechnology from the University of Delaware and a bachelor’s degree in biotechnology from Sharda University in India.

“I am excited to join Science Exchange — the most trusted outsourcing platform for scientific products and services,” said Singh. “Science Exchange is a trailblazing company that is revolutionizing R&D outsourcing by helping companies around the world bring their innovations to market faster. I can’t think of a better place to be.”

Elizabeth Iorns, Ph.D., Named 2017 Scrip Award Executive of the Year Finalist

November 1, 2017 | Posted by Team in Company, Events, Press Release, Science Exchange News |

Scrip Award Finalist Elizabeth Iorns

PALO ALTO CA, November 1, 2017 –  Science Exchange, the world’s leading and most secure platform for outsourced research and development (R&D), announced today that company CEO and co-founder Elizabeth Iorns, Ph.D., has been selected as an Executive of the Year finalist in the prestigious 2017 Scrip Awards.

Dr. Iorns is one of six C-level executives recognized in the Executive of the Year category for private companies or those with a market capitalization of <$1 billion. This awards category acknowledges excellence in the leadership of large and small pharmaceutical and biotechnology companies around the world.

A cancer researcher herself, Iorns co-founded Science Exchange in 2011 to streamline R&D outsourcing and facilitate access to qualified, innovative scientific service providers. Because of the robust platform’s clear benefits to R&D organizations, she has successfully negotiated enterprise-level agreements between Science Exchange and many of the world’s top biopharma companies, as well as with numerous biotech and pharma startup incubators. Over the past year, in addition to expanding the company’s reach into other R&D reliant industries like agrisciences and cosmetics, Iorns led the a successful Series C venture capital funding round, bringing an additional $28 million of investment that will allow Science Exchange to accelerate its impressive growth.

Iorns is also the co-director of the Reproducibility Initiative, and is a part-time partner at Y Combinator. She has a Ph.D. in Cancer Biology from the Institute of Cancer Research (UK), and before starting Science Exchange was an Assistant Professor at the University of Miami, where she remains an Adjunct Professor. She has been recognized previously as one of Nature’s “Ten People that Mattered” and WIRED’s “50 Women Who Are Changing The World.”

In its 13th year, the Scrip Awards program recognizes the key roles that pharmaceutical, biotech and other related industries play in improving healthcare around the world. A panel of 16 highly respected and independent experts from across diverse sectors evaluated the award entries to select the finalists. The winners across 16 categories will be announced at the 13th Annual Scrip Awards ceremony at the London Hilton on Park Lane in London, England on November 29, 2017. For more details on the event, visit www.ScripAwards.com.  

About Science Exchange

We are transforming scientific collaboration by creating a marketplace where scientists can order experiments from the world's top labs.

Check the Science Exchange blog for updates, opinions, guest posts and the latest happenings at Science Exchange HQ!

Visit Science Exchange →

Subscribe to the blog
Never miss a post! Science Exchange blog posts delivered right to your inbox.
Thank you for joining the SciEx revolution!
Powered By WPFruits.com